Sandoz Sues Amgen Over Enbrel Biosimilar
By Jared Foretek · April 14, 2025, 3:09 PM EDT
Sandoz accused Amgen of illegally blocking biosimilar competition to its blockbuster Enbrel drug for arthritis and other inflammatory diseases, alleging that the company used strategic acquisitions and illegal patent extensions to...
To view the full article, register now.